Company intelligence / Profile preview

Aqua Science

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Successfully commercialized BioLight line of bioluminescent reagents and the BioLight Toxy instrument for rapid field and lab-based acute water toxicity testing. Completed SBIR Phase I grant to develop a rapid test kit for PFAS; Phase II proposal submitted as of July 2024. Products are used globally with significant export revenue; recognized by the US EPA with an award in June 2024.

Therapeutic areas: Other
Modalities: Bioluminescent reagentsDiagnostic deviceCustom reagents for toxicity testing
Industry: Non-Drug Biotech

Partnerships

Export DelawareDelaware Division of Small Businesstrade missions to PhilippinesDominican RepublicThailandMexico CityItaly

Beyond the preview

Go deeper on Aqua Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aqua Science.

Explore the full profile